PE20141028A1 - Nuevos moduladores y metodos para su uso - Google Patents

Nuevos moduladores y metodos para su uso

Info

Publication number
PE20141028A1
PE20141028A1 PE2013001935A PE2013001935A PE20141028A1 PE 20141028 A1 PE20141028 A1 PE 20141028A1 PE 2013001935 A PE2013001935 A PE 2013001935A PE 2013001935 A PE2013001935 A PE 2013001935A PE 20141028 A1 PE20141028 A1 PE 20141028A1
Authority
PE
Peru
Prior art keywords
seq
group
antibody
methods
presents
Prior art date
Application number
PE2013001935A
Other languages
English (en)
Inventor
Orit Foord
Scott J Dylla
Robert A Stull
Alex Bankovich
Alexandra Leida L Lazetic
Jeffrey Bernstein
Original Assignee
Stem Centrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/050451 external-priority patent/WO2012031280A2/en
Application filed by Stem Centrx Inc filed Critical Stem Centrx Inc
Publication of PE20141028A1 publication Critical patent/PE20141028A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

SE REFIERE A UN MODULADOR AISLADO, CARACTERIZADO PORQUE ES UN MODULADOR DE LA PTK7, QUE CONTIENE UN ANTICUERPO MONOCLONAL QUE SE SELECCIONA DEL GRUPO QUE CONSISTE DE UN ANTICUERPO QUIMERICO, ANTICUERPO HUMANIZADO Y UN ANTICUERPO HUMANO. DICHO ANTICUERPO MONOCLONAL COMPRENDE: a) UNA REGION VARIABLE DE LA CADENA LIVIANA QUE PRESENTA UNA SECUENCIA DE AMINOACIDO DEL GRUPO QUE CONSISTE EN LA SEQ ID N� 20, SEQ ID N�22, SEQ ID N�24, ENTRE OTROS; Y b) UNA REGION VARIABLE DE LA CADENA PESADA QUE PRESENTA UNA SECUENCIA DE AMINOACIDO DEL GRUPO QUE CONSISTE EN LA SEQ ID N� 21, SEQ ID N� 23, SEQ ID N�25, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA TRATAR UN TRASTORNO HIPERPROLIFERATIVO QUE COMPRENDE UN TRASTORNO NEOPLASICO.
PE2013001935A 2011-02-18 2012-02-17 Nuevos moduladores y metodos para su uso PE20141028A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161444614P 2011-02-18 2011-02-18
PCT/US2011/050451 WO2012031280A2 (en) 2010-09-03 2011-09-02 Identification and enrichment of cell subpopulations
PCT/US2012/025726 WO2012112943A1 (en) 2011-02-18 2012-02-17 Novel modulators and methods of use

Publications (1)

Publication Number Publication Date
PE20141028A1 true PE20141028A1 (es) 2014-08-30

Family

ID=46672972

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013001935A PE20141028A1 (es) 2011-02-18 2012-02-17 Nuevos moduladores y metodos para su uso
PE2018001014A PE20181076A1 (es) 2011-02-18 2012-02-17 Nuevos moduladores y metodos para su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018001014A PE20181076A1 (es) 2011-02-18 2012-02-17 Nuevos moduladores y metodos para su uso

Country Status (31)

Country Link
US (3) US9409995B2 (es)
EP (2) EP2675827B1 (es)
JP (2) JP6296796B2 (es)
KR (1) KR102022734B1 (es)
CN (2) CN107056945A (es)
AR (1) AR085281A1 (es)
AU (3) AU2012219313C1 (es)
BR (1) BR112013021134B1 (es)
CA (1) CA2827637C (es)
CO (1) CO6791571A2 (es)
CY (1) CY1123551T1 (es)
DK (1) DK2675827T3 (es)
ES (1) ES2829206T3 (es)
HR (1) HRP20201399T1 (es)
HU (1) HUE050657T2 (es)
IL (3) IL228018A (es)
LT (1) LT2675827T (es)
MX (1) MX356434B (es)
MY (1) MY173880A (es)
PE (2) PE20141028A1 (es)
PH (1) PH12018500452A1 (es)
PL (1) PL2675827T3 (es)
PT (1) PT2675827T (es)
RS (1) RS60841B1 (es)
RU (2) RU2627176C2 (es)
SA (1) SA112330278B1 (es)
SG (2) SG10201603926SA (es)
SI (1) SI2675827T1 (es)
TW (2) TWI696635B (es)
WO (1) WO2012112943A1 (es)
ZA (1) ZA201306958B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130061340A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
CN106434561A (zh) 2010-09-03 2017-02-22 艾伯维施特姆森特克斯有限责任公司 细胞亚群的鉴定和富集
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
EP3016983B1 (en) * 2013-07-04 2018-05-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A new fusion protein to target and treat acute myloid leukemia cells
WO2015157976A1 (zh) * 2014-04-17 2015-10-22 深圳迈瑞生物医疗电子股份有限公司 细胞分析方法和系统、装置
LT3137114T (lt) * 2014-04-30 2021-03-25 Pfizer Inc. Anti-ptk7 antikūnų ir vaistų konjugatai
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
BR112020016859A2 (pt) 2018-02-28 2020-12-29 Pfizer Inc. Variantes de il-15 e usos da mesma
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
PE20210127A1 (es) 2018-05-23 2021-01-19 Pfizer Anticuerpos especificos para cd3 y sus usos
WO2020014175A1 (en) * 2018-07-10 2020-01-16 Children's Medical Center Corporation Methods and compositions for analyzing immortalized megakaryocyte progenitor cell lines and platelet-like particles derived therefrom
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
EP4076522A4 (en) * 2019-12-16 2024-04-10 2Seventy Bio Inc ANTI-BCMA-CAR ANTIBODIES, CONJUGATES AND METHODS OF USE
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CA3164804A1 (en) 2019-12-18 2021-06-24 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
WO2021181233A2 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
CA3182887A1 (en) 2020-05-13 2021-11-18 Pfizer Inc. Methods, therapies and uses for treating cancer
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
IL300884A (en) 2020-09-14 2023-04-01 Pfizer Treatment methods and uses for cancer treatment
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023108101A1 (en) * 2021-12-09 2023-06-15 Emory University Antibodies that inhibit glycoprotein ib-ix mediated platelet signaling and uses in managing bleeding conditions
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
WO2024009191A1 (en) 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024080325A1 (ja) * 2022-10-14 2024-04-18 Jsr株式会社 抗体及びその使用

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265551A (en) 1977-07-13 1981-05-05 U.S. Philips Corporation Drive for transporting and reversing an ink ribbon, and for withdrawing the printing head in printing devices
US4111824A (en) 1977-07-21 1978-09-05 Gulf Research & Development Co. Liquid dielectric composition based on a fraction derived from the alkylation product of benzene with ethylene
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
CA2478239A1 (en) 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
CA2499580A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
EP3150630A1 (en) 2002-09-27 2017-04-05 Xencor Inc. Optimized fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
RU2366716C2 (ru) * 2003-10-24 2009-09-10 Эсбатек Аг Способ идентификации и/или проверки ингибиторов рецепторных тирозинкиназ
AU2005267722B2 (en) 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
CA2577329A1 (en) 2004-08-16 2006-03-02 Medimmune, Inc. Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006052409A2 (en) 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
SG177194A1 (en) * 2005-12-08 2012-01-30 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies
US8058252B2 (en) 2005-12-30 2011-11-15 Institut Gustave Roussy Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
SG170750A1 (en) 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
US20070292414A1 (en) 2006-06-06 2007-12-20 Christopher Duntsch Compositions enriched in neoplastic stem cells and methods comprising same
CA2923381A1 (en) 2006-09-07 2008-03-13 Arthur E. Frankel Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP2109668A4 (en) 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
WO2008149803A1 (ja) * 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
EP2190481B1 (en) 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
WO2009070767A2 (en) * 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2229187A2 (en) * 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
US8384551B2 (en) 2008-05-28 2013-02-26 MedHab, LLC Sensor device and method for monitoring physical stresses placed on a user
EP2207803B1 (en) 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
JP2012514458A (ja) * 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
WO2010081171A2 (en) 2009-01-12 2010-07-15 Cyntellect, Inc. Laser mediated sectioning and transfer of cell colonies
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
FR2964148A1 (fr) 2010-08-30 2012-03-02 Peugeot Citroen Automobiles Sa Boite de degazage destinee au circuit de refroidissement d'un moteur thermique de vehicule automobile
CN106434561A (zh) 2010-09-03 2017-02-22 艾伯维施特姆森特克斯有限责任公司 细胞亚群的鉴定和富集
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
LT3137114T (lt) * 2014-04-30 2021-03-25 Pfizer Inc. Anti-ptk7 antikūnų ir vaistų konjugatai
WO2016064749A2 (en) 2014-10-20 2016-04-28 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Also Published As

Publication number Publication date
CO6791571A2 (es) 2013-11-14
AR085281A1 (es) 2013-09-18
PT2675827T (pt) 2020-10-29
SG192816A1 (en) 2013-09-30
AU2012219313A1 (en) 2013-05-02
MX2013009541A (es) 2014-04-30
CA2827637C (en) 2020-08-11
RU2013141976A (ru) 2015-03-27
EP3763388A1 (en) 2021-01-13
MX356434B (es) 2018-05-29
KR102022734B1 (ko) 2019-09-19
PE20181076A1 (es) 2018-07-04
BR112013021134A8 (pt) 2017-07-11
RU2017126476A (ru) 2019-01-31
US9914784B2 (en) 2018-03-13
IL254062B (en) 2018-11-29
IL228018A0 (en) 2013-09-30
AU2012219313B2 (en) 2017-02-02
CY1123551T1 (el) 2022-03-24
CN103547597A (zh) 2014-01-29
US20160272723A1 (en) 2016-09-22
JP6296796B2 (ja) 2018-03-28
AU2017202934A1 (en) 2017-05-25
PL2675827T3 (pl) 2021-01-25
US9409995B2 (en) 2016-08-09
TW201309729A (zh) 2013-03-01
CN107056945A (zh) 2017-08-18
RS60841B1 (sr) 2020-10-30
CA2827637A1 (en) 2012-08-30
US20140105888A1 (en) 2014-04-17
RU2627176C2 (ru) 2017-08-03
JP2018104409A (ja) 2018-07-05
JP2014511179A (ja) 2014-05-15
AU2012219313C1 (en) 2017-05-25
PH12018500452A1 (en) 2019-11-18
US20180162952A1 (en) 2018-06-14
SI2675827T1 (sl) 2020-11-30
IL254062A0 (en) 2017-10-31
AU2019201258A1 (en) 2019-03-14
BR112013021134A2 (pt) 2016-11-29
US10836831B2 (en) 2020-11-17
WO2012112943A1 (en) 2012-08-23
IL263020A (en) 2018-12-31
BR112013021134B1 (pt) 2022-12-27
TW201800421A (zh) 2018-01-01
LT2675827T (lt) 2020-10-26
MY173880A (en) 2020-02-26
NZ615285A (en) 2015-09-25
ZA201306958B (en) 2022-03-30
HRP20201399T1 (hr) 2020-11-27
IL228018A (en) 2017-09-28
SG10201603926SA (en) 2016-07-28
KR20140018905A (ko) 2014-02-13
ES2829206T3 (es) 2021-05-31
TWI696635B (zh) 2020-06-21
EP2675827B1 (en) 2020-08-05
EP2675827A1 (en) 2013-12-25
HUE050657T2 (hu) 2021-01-28
TWI624476B (zh) 2018-05-21
SA112330278B1 (ar) 2015-10-09
DK2675827T3 (da) 2020-09-07
NZ708615A (en) 2017-02-24
CN103547597B (zh) 2017-03-15

Similar Documents

Publication Publication Date Title
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
EA202192736A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с псма
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR083747A1 (es) Anticuerpos anti-il-23
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
AR103173A1 (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20141413A1 (es) Formulaciones de anticuerpo y metodos

Legal Events

Date Code Title Description
FG Grant, registration